At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 80 enrolled
Drug / intervention
POLAT-001 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label Comparison of the Safety and Efficacy of Subconjunctival Liposomal Latanoprost (POLAT-001) to Latanoprost Ophthalmic Solution in Patients With Ocular Hypertension and Primary Open Angle Glaucoma
In Brief
A Phase 2 clinical trial evaluating POLAT-001 and Latanoprost ophthalmic solution for Glaucoma. Completed, enrolled 80 participants across 1 site.
Detailed Summary
This is an open-label, randomized, multi-center, active-controlled parallel-comparison of POLAT-001 to latanoprost ophthalmic solution in patients with ocular hypertension and primary open-angle glaucoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 2015
Enrollment StartJul 2015
Primary CompletionApr 2016
TodayJul 2026
First PostedJun 9, 2015
Enrollment StartJul 1, 2015
Primary CompletionApr 1, 2016
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 11.1 years ago
Interventions
POLAT-001drug
Subconjunctival injection
Latanoprost ophthalmic solutiondrug
Latanoprost ophthalmic solution q.d., evening